Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Research

ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138

Authors: Haiyan Chen, Qian Xiao, Yeting Hu, Liubo Chen, Kai Jiang, Yang Tang, Yinuo Tan, Wangxiong Hu, Zhanhuai Wang, Jinjie He, Yue Liu, Yibo Cai, Qi Yang, Kefeng Ding

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

Angiopoietin-like protein 1 (ANGPTL1) has been reported to suppress migration and invasion in lung and breast cancer, acting as a novel tumor suppressor candidate. Nevertheless, its effects on colorectal cancer (CRC) remain poorly defined. In this study, we aim to demonstrate the biological function of ANGPTL1 in CRC cells.

Methods

We explored ANGPTL1 mRNA expression in human CRC tissues and its association with prognosis. CRC cell lines overexpressing ANGPTL1 or with ANGPTL1 knocked down were constructed and analyzed for changes in proliferation, colony formation, migration and invasion. ANGPTL1-regulated microRNAs were analyzed, and microRNA inhibitor and mimics were used to explore the role of microRNA in ANGPTL1-associated biological function.

Results

ANGPTL1 mRNA expression was down-regulated in CRC tissues, and high ANGPTL1 expression predicted better survival in CRC patients. ANGPTL1 overexpression resulted in suppressed migration and invasion in vitro, and it prolonged overall survival in mouse models. By contrast, its down-regulation enhanced migration and invasion of CRC cells. MicroRNA-138 expression was positively correlated with ANGPTL1 mRNA level in CRC tissues and up-regulated by ANGPTL1 in CRC cells. In addition, the microRNA-138 inhibitor or mimics could reverse or promote the ANGPTL1-mediated inhibition of the migratory capacity of CRC cells, respectively.

Conclusions

This study is the first to demonstrate the biological function of ANGPTL1 in CRC cells. ANGPTL1 expression was down-regulated in CRC tissues and inversely correlated with poor survival. ANGPTL1 repressed migration and invasion of CRC cells, and microRNA-138 was involved in this process.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol. 2012;4(4):68–70.CrossRefPubMedPubMedCentral

Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed

Hu W, Li X, Wang T, Zheng S. Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget. 2016;7(42):68270–7.PubMedPubMedCentral

Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol. 2014;5:4.CrossRef

Oike Y, Yasunaga K, Suda T. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int J Hematol. 2004;80(1):21–8.CrossRefPubMed

Kuo T-C, Tan C-T, Chang Y-W, Hong C-C, Lee W-J, Chen M-W, et al. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest. 2013;123(3):1082–95.CrossRefPubMedPubMedCentral

Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, et al. Angioarrestin An Antiangiogenic Protein with Tumor-inhibiting Properties. Cancer Res. 2002;62(13):3834–41.PubMed

Xu Y, Liu Y-J, Yu Q. Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res. 2004;64(17):6119–26.CrossRefPubMed

10.

Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye Z, et al. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther. 2003;14(11):1089–105.CrossRefPubMed

11.

Xiao Q, Hu Y, Liu Y, Wang Z, Geng H, Hu L, et al. BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2. PLoS One. 2014;9(3):e91782.CrossRefPubMedPubMedCentral

12.

Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, et al. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal. 2015;8(388):ra77.CrossRefPubMedPubMedCentral

13.

Zhang Y, Davis C, Ryan J, Janney C, Pena MM. Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin Exp Metastasis. 2013;30(7):903–18.CrossRefPubMed

14.

Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, et al. A preclinical murine model of hepatic metastases. J Vis Exp. 2014;91:51677.

15.

Rajendran S, Salwa S, Gao X, Tabirca S, O’Hanlon D, O’Sullivan GC, et al. Murine bioluminescent hepatic tumour model. J Vis Exp. 2010;41.

16.

Flatmark K, Mælandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer. 2004;40(10):1593–8.CrossRefPubMed

17.

Long L, Huang G, Zhu H, Guo Y, Liu Y, Huo J. Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med. 2013;11:275.CrossRefPubMedPubMedCentral

18.

Sasaki H, Moriyama S, Sekimura A, Mizuno K, Yukiue H, Konishi A, et al. Angioarrestin mRNA expression in early-stage lung cancers. Eur J Surg Oncol. 2003;29(8):649–53.CrossRefPubMed

19.

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–24.CrossRefPubMed

20.

Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–33.CrossRefPubMedPubMedCentral

21.

Chi Y, Zhou D. MicroRNAs in colorectal carcinoma--from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43.CrossRefPubMedPubMedCentral

22.

Zhang W, Zhang T, Jin R, Zhao H, Hu J, Feng B, et al. MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res. 2014;33:113.CrossRefPubMedPubMedCentral

23.

Li T, Lai Q, Wang S, Cai J, Xiao Z, Deng D, et al. MicroRNA-224 sustains Wnt/beta-catenin signaling and promotes aggressive phenotype of colorectal cancer. J Exp Clin Cancer Res. 2016;35:21.CrossRefPubMedPubMedCentral

24.

Sha HH, Wang DD, Chen D, Liu SW, Wang Z, Yan DL, et al. MiR-138: A promising therapeutic target for cancer. Tumour Biol. 2017;39(4):1010428317697575.CrossRefPubMed

25.

Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer. 2010;127(3):505–12.CrossRefPubMedPubMedCentral

26.

Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J, et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12(5):1307–11.PubMed

27.

Munoz-Rodriguez JL, Vrba L, Futscher BW, Hu C, Komenaka IK, Meza-Montenegro MM, et al. Differentially expressed microRNAs in postpartum breast cancer in Hispanic women. PLoS One. 2015;10(4):e0124340.CrossRefPubMedPubMedCentral

28.

Datta J, Islam M, Dutta S, Roy S, Pan Q, Teknos TN. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol. 2016;56:32–9.CrossRefPubMedPubMedCentral

29.

Garcia-Cruz R, Camats M, Calin GA, Liu CG, Volinia S, Taccioli C, et al. The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model. BMC Med Genet. 2015;16:46.CrossRefPubMedPubMedCentral

30.

Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, et al. MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother. 2016;77:135–41.CrossRefPubMed

Title: ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138
Authors: Haiyan Chen
Qian Xiao
Yeting Hu
Liubo Chen
Kai Jiang
Yang Tang
Yinuo Tan
Wangxiong Hu
Zhanhuai Wang
Jinjie He
Yue Liu
Yibo Cai
Qi Yang
Kefeng Ding
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0548-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer

Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the Hedgehog signaling pathway

Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition

Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma

Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer